Market Overview:
The global cystoid macular edema market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing prevalence of age-related macular degeneration, rising awareness about eye health, and technological advancements in the field of ophthalmology. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, the global cystoid macular edema market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), anti-vascular endothelial growth factor (VEGF) agents, carbonic anhydrase inhibitors (CAIs), and steroids. The NSAIDs segment is projected to account for the largest share of this market during the forecast period. This can be attributed to their easy availability and low cost as compared with other types of drugs used for treating cystoid macular edema.
Product Definition:
Cystoid macular edema is a condition that can cause vision problems. It occurs when fluid accumulates in the central part of the retina, called the macula. The fluid makes the macula swell and causes blurred vision. Cystoid macular edema may occur as a complication of diabetes, laser eye surgery, or other eye conditions.
Non Steroidal Anti-Inflammatory Drugs:
Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat pain, inflammation and swelling caused by a variety of conditions. They can be used for the treatment of arthritis, gout, osteoarthritis and rheumatoid arthritis. Some people take them when they have acute inflammatory processes such as an injury or surgery. The most common NSAID's prescribed in the U.
Anti- Vascular Endothelial Growth Factor (VEGF) Agents:
Anti-Vascular Endothelial Growth Factor (VEGF) agents and it's usage in Cystoid Macular Edema market is expected to witness significant growth over the forecast period. The factors that propel the growth of this market include increasing incidences of eye diseases such as macular edema, diabetic retinopathy, and glaucoma along with rising awareness about anti-VEGF drugs among patients.
Application Insights:
Based on application, the global cystoid macular edema market is segmented into hospitals, ambulatory surgical centers and others. The hospital segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as a high prevalence of diabetes and other associated ophthalmic diseases that require treatment at a hospital level. Ambulatory surgical centers are anticipated to witness lucrative growth over the forecast period due to increasing awareness about eye care among individuals across various regions globally. For instance, according to an article published by NCBI in 2018, it has been estimated that around 54% of diabetic patients suffer from some form of visual impairment which requires treatment at an ambulator ysurgical center level globally.
The others segment includes optical shops or optometrists offices where patients with non-ophthalmic diseases come for vision correction or for refractive surgery procedures performed by an optometrist or ophthalmologist respectively.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing diabetic retinopathy, glaucoma, and other ophthalmic disorders. Moreover, rising adoption of advanced treatment procedures and favorable reimbursement policies are also contributing towards growth in this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure & availability of drugs at affordable prices coupled with growing target diseases such as diabetic macular edema (DME). In addition, high prevalence of diabetes is also expected drive regional market during the same period.
Growth Factors:
- Increasing prevalence of diabetes and other retinal diseases
- Rising awareness about the benefits of early diagnosis and treatment
- Growing demand for innovative therapies and devices
- Technological advancements in ophthalmic treatments and devices
- Expansion of healthcare infrastructure in emerging markets
Scope Of The Report
Report Attributes
Report Details
Report Title
Cystoid Macular Edema Market Research Report
By Type
Non Steroidal Anti-Inflammatory Drugs, Anti- Vascular Endothelial Growth Factor (VEGF) Agents, Carbonic Anhydrase Inhibitors, Steroids
By Application
Hospitals, Ambulatory Surgical Centers, Others
By Companies
EMMES, Fovea Pharmaceuticals, Icon Bioscience, Merck, Sanwa Kagaku Kenkyusho, Novartis, Johns Hopkins University, Wake Forest University, Iladevi Cataract, IOL Research Center, Rabin Medical Center, Kyushu University, Wills Eye Institute
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
152
Number of Tables & Figures
107
Customization Available
Yes, the report can be customized as per your need.
Global Cystoid Macular Edema Market Report Segments:
The global Cystoid Macular Edema market is segmented on the basis of:
Types
Non Steroidal Anti-Inflammatory Drugs, Anti- Vascular Endothelial Growth Factor (VEGF) Agents, Carbonic Anhydrase Inhibitors, Steroids
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- EMMES
- Fovea Pharmaceuticals
- Icon Bioscience
- Merck
- Sanwa Kagaku Kenkyusho
- Novartis
- Johns Hopkins University
- Wake Forest University
- Iladevi Cataract
- IOL Research Center
- Rabin Medical Center
- Kyushu University
- Wills Eye Institute
Highlights of The Cystoid Macular Edema Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Non Steroidal Anti-Inflammatory Drugs
- Anti- Vascular Endothelial Growth Factor (VEGF) Agents
- Carbonic Anhydrase Inhibitors
- Steroids
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cystoid Macular Edema Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cystoid macular edema is a condition that results from an accumulation of fluid in the center of the retina. This can lead to vision loss if not treated.
Some of the key players operating in the cystoid macular edema market are EMMES, Fovea Pharmaceuticals, Icon Bioscience, Merck, Sanwa Kagaku Kenkyusho, Novartis, Johns Hopkins University, Wake Forest University, Iladevi Cataract, IOL Research Center, Rabin Medical Center, Kyushu University, Wills Eye Institute.
The cystoid macular edema market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cystoid Macular Edema Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cystoid Macular Edema Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cystoid Macular Edema Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cystoid Macular Edema Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cystoid Macular Edema Market Size & Forecast, 2018-2028
4.5.1 Cystoid Macular Edema Market Size and Y-o-Y Growth
4.5.2 Cystoid Macular Edema Market Absolute $ Opportunity
Chapter 5 Global Cystoid Macular Edema Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cystoid Macular Edema Market Size Forecast by Type
5.2.1 Non Steroidal Anti-Inflammatory Drugs
5.2.2 Anti- Vascular Endothelial Growth Factor (VEGF) Agents
5.2.3 Carbonic Anhydrase Inhibitors
5.2.4 Steroids
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cystoid Macular Edema Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cystoid Macular Edema Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cystoid Macular Edema Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cystoid Macular Edema Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cystoid Macular Edema Analysis and Forecast
9.1 Introduction
9.2 North America Cystoid Macular Edema Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cystoid Macular Edema Market Size Forecast by Type
9.6.1 Non Steroidal Anti-Inflammatory Drugs
9.6.2 Anti- Vascular Endothelial Growth Factor (VEGF) Agents
9.6.3 Carbonic Anhydrase Inhibitors
9.6.4 Steroids
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cystoid Macular Edema Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cystoid Macular Edema Analysis and Forecast
10.1 Introduction
10.2 Europe Cystoid Macular Edema Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cystoid Macular Edema Market Size Forecast by Type
10.6.1 Non Steroidal Anti-Inflammatory Drugs
10.6.2 Anti- Vascular Endothelial Growth Factor (VEGF) Agents
10.6.3 Carbonic Anhydrase Inhibitors
10.6.4 Steroids
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cystoid Macular Edema Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cystoid Macular Edema Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cystoid Macular Edema Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cystoid Macular Edema Market Size Forecast by Type
11.6.1 Non Steroidal Anti-Inflammatory Drugs
11.6.2 Anti- Vascular Endothelial Growth Factor (VEGF) Agents
11.6.3 Carbonic Anhydrase Inhibitors
11.6.4 Steroids
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cystoid Macular Edema Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cystoid Macular Edema Analysis and Forecast
12.1 Introduction
12.2 Latin America Cystoid Macular Edema Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cystoid Macular Edema Market Size Forecast by Type
12.6.1 Non Steroidal Anti-Inflammatory Drugs
12.6.2 Anti- Vascular Endothelial Growth Factor (VEGF) Agents
12.6.3 Carbonic Anhydrase Inhibitors
12.6.4 Steroids
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cystoid Macular Edema Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cystoid Macular Edema Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cystoid Macular Edema Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cystoid Macular Edema Market Size Forecast by Type
13.6.1 Non Steroidal Anti-Inflammatory Drugs
13.6.2 Anti- Vascular Endothelial Growth Factor (VEGF) Agents
13.6.3 Carbonic Anhydrase Inhibitors
13.6.4 Steroids
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cystoid Macular Edema Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cystoid Macular Edema Market: Competitive Dashboard
14.2 Global Cystoid Macular Edema Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 EMMES
14.3.2 Fovea Pharmaceuticals
14.3.3 Icon Bioscience
14.3.4 Merck
14.3.5 Sanwa Kagaku Kenkyusho
14.3.6 Novartis
14.3.7 Johns Hopkins University
14.3.8 Wake Forest University
14.3.9 Iladevi Cataract
14.3.10 IOL Research Center
14.3.11 Rabin Medical Center
14.3.12 Kyushu University
14.3.13 Wills Eye Institute
